Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israel’s Enlivex Reports Positive Results in COVID-19 Drug Trial
Error: Contact form not found.
by Reuters and Algemeiner Staff
Parents wait with their children to enter their elementary school as it reopens following the ease of restrictions preventing the spread of the coronavirus disease (COVID-19), in Sderot, Israel, May 3, 2020. Photo: Reuters / Amir Cohen / File.
Enlivex Therapeutics Ltd on Thursday reported positive results in a clinical trial of the immunotherapy firm’s Allocetra treatment in COVID-19 patients in severe or critical condition.
Shares of Enlivex were up 83 percent in Tel Aviv after resuming trade. They were halted in Tel Aviv and on Nasdaq pending the announcement.
Israel-based Enlivex said the trial, which was conducted along with Hadassah Hospital in Jerusalem, included five patients — three in severe condition and two in critical condition.
All five had complete recoveries after an average of no more than 8.5 days following administration of Allocetra, while there were no reported severe adverse events.
It said that if approved, Allocetra “could potentially cover the gap that currently exists in treating severe or critical COVID-19 patients.”
Enlivex said that based on the positive results of the five COVID-19 patients, along with good results of Allocetra in 10 sepsis patients in a previous study, it will shift recruitment of additional patients into a larger Phase II clinical trial of COVID-19 patients in severe or critical condition as soon as possible and subject to regulatory approval.
Any COVID-19 trials would run independently of Enlivex’s planned Phase IIb clinical trial of Allocetra for the treatment of organ failures associated with sepsis expected to begin in the fourth quarter of 2020.
